Shigetec is under clinical development by EveliQure Biotechnologies and currently in Phase I for Bacillary Dysentery (Shigellosis). According to GlobalData, Phase I drugs for Bacillary Dysentery ...

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA). On Dec. 20, the FDA announced that the agency has approved Eli Lilly’s Zepbound ...

If you or a loved one is struggling with anxiety or depression, contact the Substance Abuse and Mental Health Services Administration (SAMHSA) National Helpline at 800-662-4357 for information on ...

Lower back pain can affect one's ability to move comfortably and function throughout the day. Medications, including over-the-counter (OTC) and prescription drugs, are available to manage pain and ...

While medication can provide symptom relief, it does not necessarily address underlying maladaptive behaviors, and is therefore considered by many clinicians and adjunct to treatment, rather than ...

From 2017 to 2020, it increased to 41.9%. Prescription weight loss medication has become extremely popular because it is easy to take and effective. But, it is expensive, and people must also try ...

[67] About 20% of patients with liver abscess have previously had clinical dysentery ... is effective in the treatment of invasive disease, but less effective in the treatment of luminal forms ...

Anti-obesity medications are often used to help people who have tried and not been able to lose enough weight through exercise and dietary changes. Obesity is a widespread issue affecting over 40% ...

Eli Lilly, the company that makes the blockbuster weight loss treatment Zepbound, will start studying its obesity products as treatments for alcohol and drug addiction, making it the first major ...

There are various gastroenteritis medications, including antiemetics for nausea, antibiotics for infections, and ORS for dehydration. Gastroenteritis, commonly known as the stomach flu ...

Today, the Governments of Canada and Alberta signed the National Strategy for Drugs for Rare Disease (DRD) agreement to invest a total amount of over $162 million over three years to improve access to ...